---
$id: https://graph.org.ai/products/commodity/51131815
$type: Product
source: UNSPSC
code: "51131815"
title: "Camostat"
class: "51131800"
classTitle: "Coagulants and systemic hemostatic agents"
family: "51130000"
familyTitle: "Hematolic drugs"
segment: "51000000"
segmentTitle: "Pharmaceutical Products incl. Contraceptives and Vaccines"


---

# Camostat

**UNSPSC Code**: 51131815
**Class**: [Coagulants and systemic hemostatic agents](Coagulants and systemic hemostatic agents.mdx)
**Family**: [Hematolic drugs](../Hematolic drugs.mdx)
**Segment**: [Pharmaceutical Products incl. Contraceptives and Vaccines](../../Pharmaceutical Products incl. Contraceptives and Vaccines.mdx)

This classification denotes a protease inhibitor with the molecular formula C20H22N4O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0FD207WKDU, chemically known as p-guanidinobenzoic acid, ester with (p-hydroxyphenyl)acetic acid, ester with n,n-dimethylglycolamide but generally known as camostat, which bears US NIH Compound Identifier 2536. Camostat most often comes in base and mesilate forms. European Medicines Agency schedules Camostat in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06066MIG. The term CAMOSTAT is an International Non-Proprietary Name. World Health Organization schedules camostat in its Anatomical Therapeutic Chemical (ATC) Classification. CAMOSTAT is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule camostat under HS 29252900 and SITC 51482. As of Q4 2014, CAMOSTAT remains the US FDA Preferred Term for this commodity. Camostat bears US NLM identifiers UMLS ID C0129975 and NCI Concept Code C73213. SMILES: O(C(=O)CC1CCC(OC(=O)C2CCC(/N=C(/N)N)CC2)CC1)CC(=O)N(C)C.

